ANDA 74206, held by Teva Parenteral. Dobutamine Hydrochloride.
As of Nov 16, 2026, ANDA 74206 (Dobutamine Hydrochloride), held by Teva Parenteral, was first approved by FDA on Oct 19, 1993, with 4 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 19, 1993 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Dobutamine HydrochlorideEQ 12.5MG BASE/ML ยท injectable;injection | Dobutamine Hydrochloride | Discontinued |
| Apr 1, 1997 | Supplement 4Labeling | Approved | None posted |
| Mar 3, 1997 | Supplement 3Labeling | Approved | None posted |
| Jun 2, 1995 | Supplement 2Manufacturing | Approved | None posted |
| Apr 19, 1994 | Supplement 1Manufacturing | Approved | None posted |
| Oct 19, 1993 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters